How humans make up for an 'inborn' vitamin C deficiency

A new study appears to explain how humans, along with other higher primates, guinea pigs and fruit bats, get by with what some have called an “inborn metabolic error”: an inability to produce vitamin C from glucose.

Unlike the more than 4,000 other species of mammals who manufacture vitamin C, and lots of it, the red blood cells of the handful of vitamin C-defective species are specially equipped to suck up the vitamin’s oxidized form, so-called L-dehydroascorbic acid (DHA), the researchers report in the March21st issue of Cell, a publication of Cell Press. Once inside the blood cells, that DHA--which is immediately transformed back into ascorbic acid (a.k.a. vitamin C)--can be efficiently carried through the bloodstream to the rest of the body, the researchers suggest.

“Evolution is amazing. Even though people talk about this as an ‘inborn error’—a metabolic defect that all humans have—there is also this incredible manner in which we’ve responded to the defect, using some of the body’s most plentiful cells,” said Naomi Taylor of Université Montpellier I and II in France, noting that the body harbors billions of red blood cells. “[Through evolution], we’ve created this system that takes out the oxidized form of vitamin C and transports the essential, antioxidant form.”

Meanwhile, the red cells of other mammals apparently take up very little, if any, DHA, which might explain why they need to produce so much more vitamin C than we need to get from our diets, Taylor said. The recommended daily dose of vitamin C for humans is just one mg/kg, while goats, for example, produce the vitamin at a striking rate of 200 mg/kg each day.

In essence, the red cells of animals that can’t make vitamin C recycle what little they’ve got. Earlier studies had described the recycling process, Taylor said. “Our contribution to the whole story is to show that this process of recycling exists specifically in mammals that don’t make vitamin C.”

Scientists knew that the protein called Glut1, found in the membranes of cells throughout the body, is the primary transporter of glucose. They also knew that Glut1 can transport DHA too, thanks to the structural similarities between the two molecules. In biochemical assays, it appeared that the glucose transporter would move glucose and DHA interchangeably.

But, in the new study, Taylor’s group made a surprising discovery: The Glut1 on human red blood cells strongly favors DHA over glucose. In fact, the human blood cells are known to carry more Glut1 than any other cell type, harboring more than 200,000 molecules on the surface of every cell. Nevertheless, the researchers found, as red blood cells develop in the bone marrow, their transport of glucose declines even as Glut1 numbers skyrocket.

The key to the glucose transporters switch to DHA, they show, is the presence of another membrane protein called stomatin. (Accordingly, in patients with a rare genetic disorder of red cell membrane permeability wherein stomatin is only present at low levels, DHA transport is decreased by 50% while glucose uptake is significantly increased, they report.)